PapersFlow Research Brief
Pleural and Pulmonary Diseases
Research Guide
What is Pleural and Pulmonary Diseases?
Pleural and pulmonary diseases encompass a cluster of medical conditions involving the pleura and lungs, including pleural effusion, empyema, pneumothorax, and tuberculous pleural effusion, with key diagnostic and management approaches such as thoracoscopy, pleurodesis, pleural catheter insertion, and thoracentesis.
This field covers 72,741 published works on the diagnosis and management of pleural diseases like pleural effusion, empyema, pneumothorax, malignant pleural effusion, parapneumonic effusions, and tuberculous pleural effusion. Procedures central to management include thoracoscopy, pleurodesis, pleural catheter insertion, and thoracentesis. Growth rate over the past five years is not available in the provided data.
Topic Hierarchy
Research Sub-Topics
Malignant Pleural Effusion Management
This sub-topic evaluates talc pleurodesis, indwelling pleural catheters, and systemic therapies for symptom palliation in cancer patients. Researchers conduct randomized trials comparing drainage efficacy and complication profiles.
Parapneumonic Effusion and Empyema
This sub-topic classifies effusion stages and assesses fibrinolytics versus surgical drainage in complicated cases. Researchers analyze microbiology, biomarkers, and outcomes in pediatric/adult cohorts.
Spontaneous Pneumothorax Treatment
This sub-topic compares conservative management, needle aspiration, and video-assisted thoracoscopic surgery (VATS) for primary/secondary pneumothorax. Researchers study recurrence predictors and optimal timing protocols.
Medical Thoracoscopy Techniques
This sub-topic advances diagnostic/therapeutic rigid-flexible thoracoscopy for undiagnosed effusions and pleurodesis. Researchers evaluate sedation regimens, biopsy yields, and training paradigms.
Tuberculous Pleural Effusion
This sub-topic investigates immune responses, pleural fluid diagnostics, and adjunctive corticosteroid roles in TB pleurisy. Researchers perform meta-analyses on culture-negative cases and latent TB activation risks.
Why It Matters
Pleural and pulmonary diseases impact patient survival and quality of life through targeted diagnostics and interventions. "Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma" (2003) showed that pemetrexed plus cisplatin improved median survival from 6-9 months with cisplatin alone in patients with this rapidly progressing malignancy. "Pleural Effusions: The Diagnostic Separation of Transudates and Exudates" (Light et al., 1972) established criteria using pleural-fluid protein and LDH levels, correctly classifying 47 transudates and 98 exudates in a study of 150 effusions, enabling precise separation for underlying cause identification. "Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010" (MacDuff et al., 2010) provides evidence-based strategies, noting greater symptoms in secondary spontaneous pneumothorax (SSP) versus primary (PSP), influencing intervention based on breathlessness and respiratory distress.
Reading Guide
Where to Start
"Pleural Effusions: The Diagnostic Separation of Transudates and Exudates" (Light et al., 1972) because it provides foundational diagnostic criteria validated in 150 effusions, essential for understanding pleural disease evaluation.
Key Papers Explained
"Pleural Effusions: The Diagnostic Separation of Transudates and Exudates" (Light et al., 1972) establishes core separation criteria using protein and LDH, cited 1747 times. "Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010" (MacDuff et al., 2010) builds on diagnostics by outlining symptom-based management strategies for pneumothorax. "Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma" (Vogelzang et al., 2003) extends to therapeutic advances, demonstrating survival gains in a specific pleural malignancy. "An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias" (Travis et al., 2013) updates prior classifications, connecting interstitial pneumonias to broader pulmonary disease frameworks.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints and news coverage from the last 12 months are not available, limiting visibility into immediate frontiers. Top papers highlight ongoing needs in refining classifications as in Travis et al. (2013) and optimizing therapies like those in Vogelzang et al. (2003).
Papers at a Glance
Frequently Asked Questions
What criteria separate transudative from exudative pleural effusions?
Light et al. (1972) in "Pleural Effusions: The Diagnostic Separation of Transudates and Exudates" evaluated pleural-fluid cell counts, protein, and LDH levels in 150 effusions. Preset criteria classified 47 as transudates and 98 as exudates with high accuracy. These metrics distinguish based on fluid characteristics tied to underlying pathophysiology.
How does pemetrexed plus cisplatin affect survival in malignant pleural mesothelioma?
"Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma" (Vogelzang et al., 2003) conducted a phase III trial in patients with median survival of 6-9 months. Combination therapy improved survival compared to cisplatin alone. This established a standard chemotherapy approach for this malignancy.
What are the management guidelines for spontaneous pneumothorax?
"Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010" (MacDuff et al., 2010) states symptoms may be minimal in primary spontaneous pneumothorax (PSP) but greater in secondary (SSP), even with small size. Breathlessness influences strategy, and severe respiratory distress indicates prompt intervention. Guidelines emphasize clinical evaluation for decision-making.
What defines the classification of idiopathic interstitial pneumonias?
"An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias" (Travis et al., 2013) supplements the 2002 classification, outlining advances over the past decade. It addresses idiopathic interstitial pneumonias relevant to pulmonary diseases. The update identifies areas for future investigation.
What is the role of lung-volume-reduction surgery in severe emphysema?
"A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema" (Fishman, 2003) found surgery improves exercise capacity but offers no overall survival advantage over medical therapy. It provides a survival benefit for patients with predominantly upper-lobe emphysema and low baseline exercise capacity. Results guide patient selection for this intervention.
What are standards for COPD patient care including surgery?
"Standards for the Diagnosis and Care of Patients with Chronic Obstructive Pulmonary Disease" (Celli et al., 1995) summarizes surgical approaches, recommending pulmonary function studies before lung resection. Simple spirometry assesses physiologic operability with FEV1 > 2 L indicating suitability. These standards apply to COPD management in pulmonary disease contexts.
Open Research Questions
- ? How can diagnostic accuracy for distinguishing transudates from exudates be improved beyond protein and LDH criteria in diverse patient populations?
- ? What factors predict survival benefits from pemetrexed-cisplatin in malignant pleural mesothelioma beyond baseline characteristics?
- ? In which emphysema subtypes does lung-volume-reduction surgery confer the greatest survival advantage over medical therapy?
- ? What pathogenetic mechanisms drive progression in idiopathic pulmonary fibrosis, and how do they inform targeted therapies?
- ? How do symptom profiles in primary versus secondary spontaneous pneumothorax guide optimal intervention thresholds?
Recent Trends
No recent preprints from the last 6 months or news coverage from the last 12 months are available.
The field maintains 72,741 works with highly cited papers from 1972-2013, such as Light et al. at 1747 citations and MacDuff et al. (2010) at 1456 citations, indicating sustained reliance on established diagnostics and guidelines.
1972Research Pleural and Pulmonary Diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Pleural and Pulmonary Diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers